Skip to content
DataLookout
Menu

LIFTNCT07936760

Life After ICU With Fufang E'Jiao Jiang: Effects on Hierarchical Clinical Benefit and Health-Related Quality of Life in Critical Illness Survivors-A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (LIFT)

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Nov 30, 2026 to Nov 16, 2026
    • Site details revised at 13 of 13 sites
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Win Ratio for the 90-Day Hierarchical Composite Outcome
Timeframe: From randomization through day 90

Secondary (30)

6-minute walk test distance
Clinical Frailty Scale score
Montreal Cognitive Assessment score
Fatigue Severity Scale score
Hospital Anxiety and Depression Scale score
Show 25 moreShow less
Total Sleep Time Measured by Wrist Actigraphy
Sleep Efficiency Measured by Wrist Actigraphy
Wake After Sleep Onset Measured by Wrist Actigraphy
Global Score on the Pittsburgh Sleep Quality Index (PSQI)
Appetite
Handgrip strength
Body Fat Percentage Measured by Nutrilab Body Composition Analysis
Fat Mass Measured by Nutrilab Body Composition Analysis
Skeletal Muscle Mass Measured by Nutrilab Body Composition Analysis
Fat-Free Mass Measured by Nutrilab Body Composition Analysis
Hemoglobin Concentration
Albumin Concentration
Prealbumin Concentration
C-Reactive Protein Concentration
Creatinine Concentration
Blood Urea Nitrogen Concentration
Red Blood Cell Count
Absolute Lymphocyte Count
White Blood Cell Count
Percentage of HLA-DR-Positive Cells
Absolute Reticulocyte Count
Reticulocyte Hemoglobin Content (RET-He or CHr)
Serum Ferritin Concentration
Transferrin Saturation (TSAT)
Plasma Growth Differentiation Factor 15 (GDF15) Concentration

Arms and interventions

Fufang Ejiao JiangExperimental

Participants will receive Fufang Ejiao Jiang, 20 mL orally three times daily for 90 consecutive days

placeboPlacebo comparator

Participants will receive a matching placebo, 20 mL orally three times daily for 90 consecutive days

Drugs: Fufang Ejiao Jiang, Matching placebo control

Sites

13 sites in 1 country